Möchten Sie immer auf dem neuesten Stand bleiben?

Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal...

Ontario takes historic steps to end invasive research on dogs and cats, but experts warn loopholes remain and stronger protections are needed.

PharmAla ships MDMA to Mt. Sinai Hospital and starts making patented novel MDMA-like drug, preparing for a phase 2 clinical trial into Social Anxiety.

BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.

LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioTech Breakthrough, an independent market intelligence organization that identifies and honors the top companies, technologies and products shaping...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...

Eclipse Energy today announced a collaborative partnership and capital investment with Weatherford International plc to commercialize subsurface cleantech.

Matisse Pharmaceuticals receives INN (International Non-proprietary Name) isupartob sodium from the WHO recognizing first-in-class drug status for M6229.

Autobahn Labs and Astellas form a strategic partnership to source and develop early-stage drug discovery programs from academia.